Literature DB >> 7823026

Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules.

J P Henry1, D Botton, C Sagne, M F Isambert, C Desnos, V Blanchard, R Raisman-Vozari, E Krejci, J Massoulie, B Gasnier.   

Abstract

Prior to secretion, monoamines (catecholamines, serotonin, histamine) are concentrated from the cytoplasm into vesicles by vesicular monoamine transporters (VMAT). These transporters also carry non-physiological compounds, e.g. the neurotoxin methyl-4-phenylpyridinium. VMAT acts as an electrogenic antiporter (exchanger) of protons and monoamines, using a proton electrochemical gradient. Vesicular transport is inhibited by specific ligands, including tetrabenazine, ketanserin and reserpine. The mechanism of transport and the biochemistry of VMAT have been analyzed with the help of these tools, using mainly the chromaffin granules from bovine adrenal glands as a source of transporter. Although biochemical studies did not suggest a multiplicity of VMATs, two homologous but distinct VMAT genes have recently been cloned from rat, bovine and human adrenal glands. The VMAT proteins are predicted to possess 12 transmembrane segments, with both extremities lying on the cytoplasmic side. They possess N-glycosylation sites in a putative luminal loop and phosphorylation sites in cytoplasmic domains. In rat, VMAT1 is expressed in the adrenal gland whereas VMAT2 is expressed in the brain. In contrast, we found that the bovine adrenal gland expressed both VMAT1 and VMAT2. VMAT2 corresponds to the major transporter of chromaffin granules, as shown by partial peptidic sequences of the purified protein and by a pharmacological analysis of the transport obtained in transfected COS cells (COS cells are monkey kidney cells possessing the ability to replicate SV-40-origin-containing plasmids). We discuss the possibility that VMAT1 may be specifically addressed to large secretory granules vesicles, whereas VMAT2 may also be addressed to small synaptic vesicles; species differences would then reflect the distinct physiological roles of the small synaptic vesicles in the adrenal gland.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7823026     DOI: 10.1242/jeb.196.1.251

Source DB:  PubMed          Journal:  J Exp Biol        ISSN: 0022-0949            Impact factor:   3.312


  29 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.

Authors:  Shingo Kariya; Nobuyuki Takahashi; Makito Hirano; Satoshi Ueno
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Vesicular monoamine transporters (VMATs) in adrenal chromaffin cells: stress-triggered induction of VMAT2 and expression in epinephrine synthesizing cells.

Authors:  Andrej Tillinger; Anne Sollas; Lidia I Serova; Richard Kvetnansky; Esther L Sabban
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

Review 5.  Membrane composition of adrenergic large and small dense cored vesicles and of synaptic vesicles: consequences for their biogenesis.

Authors:  H Winkler
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

6.  Optogenetic excitation of preBötzinger complex neurons potently drives inspiratory activity in vivo.

Authors:  Zaki Alsahafi; Clayton T Dickson; Silvia Pagliardini
Journal:  J Physiol       Date:  2015-07-14       Impact factor: 5.182

7.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

8.  Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.

Authors:  Teresa Pasqua; Sumana Mahata; Gautam K Bandyopadhyay; Angshuman Biswas; Guy A Perkins; Amiya P Sinha-Hikim; David S Goldstein; Lee E Eiden; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2015-11-16       Impact factor: 5.249

Review 9.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

10.  1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonism-inducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies.

Authors:  Agnieszka Wasik; Irena Romańska; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2009-02-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.